A case for IL-6, IL-17A, and nitric oxide in the pathophysiology of Sjögren's syndrome

International Journal of Immunopathology and Pharmacology

Volumn 29, Issue 3, 2016, Pages 386-397

  Benchabane, Sarah ^a   Boudjelida, Abdelhalim ^b   Toumi, Ryma ^a   Belguendouz, Houda ^a   Youinou, Pierre ^c   Touil Boukoffa, Chafia ^a  

^a UNIVERSITY OF SCIENCES AND TECHNOLOGY HOUARI BOUMEDIENE   (Algeria)

^b Bab El Oued Hospital   (Algeria)

^c INSERM   (France)

Author keywords

inducible nitric oxide synthase; interleukin 17A; interleukin 6; nitric oxide; primary Sj gren's syndrome

Indexed keywords

CD68 ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; NITRIC OXIDE; STEROID; TUMOR NECROSIS FACTOR ALPHA; IL17A PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; NOS2 PROTEIN, HUMAN;

ADULT; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOKINE PRODUCTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MEDIATOR; MIDDLE AGED; MONONUCLEAR CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SALIVA; SALIVARY GLAND; SALIVARY GLAND BIOPSY; SERUM; SIALOADENITIS; SJOEGREN SYNDROME; STEROID THERAPY; TISSUE INJURY; LACRIMAL APPARATUS; METABOLISM; PATHOLOGY;

ADULT; FEMALE; HUMANS; INTERLEUKIN-17; INTERLEUKIN-6; LACRIMAL APPARATUS; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; SALIVARY GLANDS; SJOGREN'S SYNDROME;

EID: 84980383424     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/0394632016651273     Document Type: Article

References (62)

1. Moutsopoulos HM, (2014) Sjögren's syndrome: A forty-year scientific journey. Journal of Autoimmunity 51: 1-9.
2. Betteli E, Carrier Y, Gao W, et al. (2006) Reciprocal development pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 441: 235-238.
3. Alunno A, Carubbi F, Bistoni O, et al. (2015) T regulatory and T helper 17 cells in primary Sjögren's syndrome: Facts and perspectives. Mediators of Inflammation 2015: 243723.
4. Youinou P, Devauchelle V, Pers JO, (2010) Significance of B cells and B cell clonality in Sjögren's syndrome. Arthritis and Rheumatism 62: 2605-2610.
5. Youinou P, Saraux A, Pers JO,. (2012) B lymphocytes govern the pathogenesis of Sjögren's syndrome. Current Pharmaceutical Biotechnology 3: 2071-2077.
6. Pers JO, Youinou P, (2016) B lymphocytes in primary Sjögren's syndrome. In: Gerli R, (ed.) Sjögren's syndrome. Amsterdam: Elsevier.
7. Youinou P, Pers JO, (2015) Primary Sjögren's syndrome at a glance today. Joint Bone Spine 82: 75-76.
8. Vitali C, Bombardieri S, Jonsson R, et al. (2002) Classification criteria for Sjögren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Annals of the Rheumatic Diseases 61: 554-558.
9. Youinou P, Pers JO, (2011) Disturbance of the cytokine network in Sjögren's syndrome. Arthritis Research & Therapy 13: 227-234.
10. Youinou P, Jamin C, (2009) The weight of IL-6 in B cell-related autoimmune diseases. Journal of Autoimmunity 32: 206-210.
11. Nguyen CQ, Yin H, Lee BH, et al. (2010) Pathogenic effect of IL-17A in induction of Sjögren's syndrome-like disease using adenovirus-mediated gene transfer. Arthritis Research & Therapy 12: R220.
12. Onishi RM, Gaffen SL, (2010) Interleukin-17 and its target genes: Mechanisms of IL-17 function in disease. Immunology 129: 311-321.
13. Mocellin S, Panelli MC, Wang E, et al. (2003) The dual role of IL-10. Trends in Immunology 4: 36-43.
14. Griffith OW, Stuehr DJ, (1995) NO synthases: Properties and catalytic mechanism. Annual Review of Physiology 57: 707-736.
15. Rettori V, Lomniczi A, Elverdin JC, et al. (2000) Control of salivary secretion by NO and its role in neuroimmunomodulation. Annals of the New York Academy of Sciences 917: 258-267.
16. Looms D, Tritsaris K, Pedersen AM, et al. (2002) NO signaling in salivary glands. Journal of Oral Pathology & Medicine 31: 569-584.
17. Wang Y, Jamal SA, Torres-Romero LF, et al. (2014) NF-κB controls resistance of human salivary gland cells to apoptosis in an in vitro model of Sjögren's syndrome. Open Journal of Rheumatology and Autoimmune Diseases 4: 178-191.
18. Touil-Boukoffa C, Bauvois B, Sanceau J, et al. (1998) Production of NO in human hydatidosis. Relationship between nitrite and IFN-3 levels. Biochimie 80: 739-744.
19. Belguendouz H, Messaoudene D, Lahmar K, et al. (2011) IFN-3 and NO production during Behçet uveitis: Immunomodulatory effect of IL-10. Journal of Interferon & Cytokine Research 31: 643-651.
20. Lappin DF, Kjeldsen M, Sander L, et al. (2000) Inducible NO synthase expression in periodontitis. Journal of Periodontal Research 35: 369-373.
21. Rafa H, Saoula H, Belkhelfa M, et al. IL-23/IL-17A axis correlates with the NO pathway in inflammatory bowel diseases: Immunomodulatory effect of retinoic acid. Journal of Interferon & Cytokine Research 37: 355-368.
22. Coleman JW, (2001) NO in immunity and inflammation. International Immunopharmacology 1: 1397-1406.
23. Pacher P, Beckman JS, Liaudet L, (2007) NO and peroxynitrite in health and disease. Physiological Reviews 87: 315-424.
24. Ibn Yacoub Y, Rostom S, Laatiris A, et al. (2012) Primary Sjögren's syndrome in Moroccan patients: Characteristics, fatigue and quality of life. Rheumatology International 32: 2637-2643.
25. Daniels TE, (1984) Labial salivary gland biopsy in Sjögren's syndrome. Assessment as a diag-nostic criterion in 362 suspected cases. Arthritis and Rheumatism 27: 147-156.
26. Daniels TE, Whitcher JP, (1974) Association of patterns of labial salivary gland inflammation with keratoconjunctivitis sicca. Analysis of 618 patients with suspected Sjögren's syndrome. Arthritis and Rheumatism 37: 869-877.
27. Tarpley TM Jr, Anderson LG, White CL, (1974) Minor salivary gland involvement in Sjögren's syndrome. Oral Surgery, Oral Medicine, and Oral Pathology 37: 64-74.
28. Peri Y, Agmon-Levin N, Theodor E, et al. (2012) Sjögren's syndrome, the old and the new. Best Practie & Research. Clinical Rheumatology 26: 105-117.
29. Kurien BT, Dsouza A, Igoe A, et al. (2013) Immunization with 60 kD Ro peptide produces different stages of preclinical autoimmunity in a Sjögren's syndrome model among multiple strains of inbred mice. Clinical and Experimental Immunology 173: 67-75.
30. Brennan MT, Sankar V, Leakan RA, et al. (2002) Risk factors for positive minor salivary gland biopsy findings in Sjögren's syndrome. Arthritis and Rheumatism 47: 189-195.
31. Radfar L, Kleiner DE, Fox PC, et al. (2002) Clinical significance of lymphocytic foci in minor salivary glands of healthy volunteers. Arthritis and Rheumatism 47: 520-524.
32. Langerman AJ, Blair EA, Sweiss NJ, et al. (2007) Utility of lip biopsy in the diagnosis and treatment of Sjögren's syndrome. Laryngoscope 117: 1004-1008
33. Gerli R, Muscat C, Giansanti M, et al. (1997) Quantitative assessment of salivary gland inflamma-tory infiltration in primary Sjögren's syndrome: Its relationship to different demographic, clinical and serological features of the disorder. British Journal of Rheumatology 36: 969-975.
34. Konttinen YT, Platts LA, Tuominen S, et al. (1997) Role of NO in Sjögren's syndrome. Arthritis and Rheumatism 40: 875-883.
35. Wanchu A, Khullar M, Sud A, et al. (2000) Elevated nitric oxide production in patients with primary Sjögren's syndrome. Clinical Rheumatology 19: 360-364.
36. Rosignoli F, Rocca V, Meiss R, et al. (2004) Inhibition of calcium-calmodulin kinase restores NO production and signaling in submandibular glands of a mouse model of salivary dysfunction. British Journal of Pharmacology 143: 1058-1065.
37. Manoussakis MN, Boiu S, Korkolopoulou P, et al. (2007) Rates of infiltration by macrophages and dendritic cells and expression of IL-18 and -12 in the chronic inflammatory lesions of Sjögren's syndrome. Arthritis and Rheumatism 56: 3977-3988.
38. Beauregard C, Brandt PC, Chiou GC, (2007) Induction of NO synthase and overproduction of NO by IL-1β in cultured lacrimal gland acinar cells. Experimental Eye Research 77: 109-114.
39. Anaya JM, Correa PA, Herrera M, et al. (2002) IL-10 influences autoimmune response in primary Sjögren's syndrome and is linked to IL-10 gene polymorphism. Journal of Rheumatology 29: 1874-1876.
40. Bertorello R, Cordone MP, Contini P, et al. (2004) Increased levels of IL-10 in saliva of Sjögren's syndrome patients. Correlation with disease activity. Clinical and Experimental Medicine 4: 148-151.
41. Park YB, Lee SK, Kim DS, et al. (1998) Elevated IL-10 levels correlated with disease activity lupus. Clinical and Experimental Rheumatology 16: 283-288.
42. Manganelli P, Fietta P, (2003) Apoptosis and Sjögren syndrome. Seminars in Arthritis and Rheumatism 33: 49-65.
43. Grisius MM, Bermudez DK, Fox PC, (1997) Salivary and serum IL-6 in primary Sjögren's syndrome. Journal of Rheumatology 24: 1089-1091.
44. Nibali L, Fedele S, D'Aiuto F, et al. (2012) IL-6 in oral diseases: A review. Oral Diseases 18: 236-243.
45. Alunno A, Bistoni O, Caterbi S, et al. (2015) Serum IL-17 in primary Sjögren's syndrome: Association with disease duration and parotid gland swelling. Clinical and Experimental Rheumatology 33: 129.
46. Katsifis GE, Rekka S, Moutsopoulos NM, et al. (2009) Systemic and local IL-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis. American Journal of Pathology 175: 1167-1177.
47. Kwok SK, Cho ML, Her YM, et al. (2012) TLR-2 ligation induces the production of IL-23/IL-17 via IL-6, STAT3 and NF-κB pathway in patients with primary Sjögren's syndrome. Arthritis Research & Therapy 14: R64.
48. Liu Y, Yin H, Zhao M, et al. (2014) TLR2 and TLR4 in autoimmune diseases: A comprehensive review. Clinical Reviews in Allergy & Immunology 47: 136-147.
49. Guerrier T, Le Pottier L, Devauchelle V, et al. (2012) Role of TLR in primary Sjögren's syndrome with special emphasis on B cell marturation within exocrine tissues. Journal of Autoimmunity 39: 69-76.
50. Sada PR, (2015) Biological treatment of Sjögren's syndrome. Rheumatology (Oxford) 54: 219-230.
51. Maini RN, Taylor PC, Szechinski J, et al. (2006) Double-blind randomized controlled clinical trial of the IL-6 receptor antogonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis and Rheumatism 5: 2817-2829.
52. Fagone P, Muthumani K, Mangano K, et al. (2014) VGX-1027 modulates genes involved in LPS-induced TLR-4 activation in a murine model of lupus. Immunology 142: 594-602.
53. Mangano K, Sardesai NY, Quattrocchi C, et al. (2008) Effects of the immunomodulator, VGX-1027, in endotoxin-induced uveitis in Lewis rats. British Journal of Pharmacology 155: 722-730.
54. Stojanovic I, Cuzzocrea S, Mangano K, et al. (2007) In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clinical Immunology 123: 311-323.
55. Hsu HC, Yang PA, Wang J, et al. (2008) Interleukin 17-producing T helper cells and IL-17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nature Immunology 9: 166-175.
56. Devauchelle V, Mariette X, Jousse S, et al. Treatment of primary Sjögren's syndrome with ritximab, a randomised trial. Annals of Internal Medicine 60: 243-242.
57. Alunno A, Carubbi F, Bistoni O, et al. (2016) IL-17-producing T lymphocytes express CD20, and are depleted by rituximab in primary Sjögren's syndrome: A pilot study. Clinical and Experimental Immunology. DOI: 10.1111/cei.12771.
58. Ciccia F, Guggino G, Rizzo A, et al. (2014) Rituximab modulates IL-17 expression in the salivary glands of patients with Sjögren's syndrome. Rheumatology (Oxford) 53: 1313-1320.
59. Takemura S, Klimiuk PA, Braun A, et al. (2001) T cell activation in rheumatoid synovium is B cell-dependent. Journal of Immunology 167: 4710-4718.
60. Hillion S, Dueymes M, Youinou P, et al. (2007) Il-6 contributes to the expression of Rags in human mature B cells. Journal of Immunology 179: 6790-6798.
61. Barr TA, Shen P, Brown S, et al. (2012) B cell depletion therapy ameliorates autoimmune disease through ablation of Il-6-producing B cells. Journal of Experimental Medicine 209: 1001-1008.
62. Le Dantec C, Varin MM, Brooks WH, et al. (2012) Epigenetics and Sjögren's syndrome. Current Pharmaceutical Biotechnology 13: 2046-2053.